We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
argenx
ARGX
$54.8B
| $39.3M | 0.07% |
277,544
+6,016
| +2% | +$764K |
|
102
Booking.com
BKNG
$156B
| $39.3M | 0.07% |
523,425
+32,325
| +7% | +$2.32M |
|
103
Vistra
VST
$47.7B
| $38.1M | 0.07% |
1,684,352
+57,357
| +4% | +$1.44M |
|
104
Mercury Systems
MRCY
$6.53B
| $37.2M | 0.07% |
528,895
+139,776
| +36% | +$9.7M |
|
|
GLIBA
105
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $36.8M | 0.07% |
599,464
+41,919
| +8% | +$2.49M |
|
106
Cactus
WHD
$5.5B
| $36.8M | 0.07% |
1,112,289
+59,893
| +6% | +$2.08M |
|
107
Rapid7
RPD
$694M
| $36.7M | 0.07% |
634,957
-5,211
| -0.8% | -$274K |
|
108
Q2 Holdings
QTWO
$3.95B
| $36.6M | 0.07% |
478,763
-18,015
| -4% | -$1.3M |
|
|
109
Euronet Worldwide
EEFT
$2.73B
| $36.1M | 0.07% |
214,639
-276,479
| -56% | -$42.3M |
|
|
BPMC
110
DELISTED
Blueprint Medicines
BPMC
| $35.4M | 0.07% |
375,268
+4,501
| +1% | +$371K |
|
|
TCF
111
DELISTED
TCF Financial Corporation Common Stock
TCF
| $35.4M | 0.07% |
860,402
+135,657
| +19% | +$5.63M |
|
112
FIVE9
FIVN
$2.17B
| $34.6M | 0.06% |
675,552
+33,116
| +5% | +$1.68M |
|
113
Ingersoll Rand
IR
$34.2B
| $34.4M | 0.06% |
994,811
-5,605
| -0.6% | -$181K |
|
|
ENV
114
DELISTED
ENVESTNET, INC.
ENV
| $34.1M | 0.06% |
498,268
-21,538
| -4% | -$1.48M |
|
115
Novanta
NOVT
$5.82B
| $33.8M | 0.06% |
358,401
+101,102
| +39% | +$8.63M |
|
116
Trex
TREX
$4.93B
| $33.5M | 0.06% |
935,416
+45,938
| +5% | +$1.56M |
|
117
Supernus Pharmaceuticals
SUPN
$2.72B
| $33.2M | 0.06% |
1,003,429
+578,301
| +136% | +$19.8M |
|
118
Churchill Downs
CHDN
$6.06B
| $33.1M | 0.06% |
575,880
+45,632
| +9% | +$2.29M |
|
119
Littelfuse
LFUS
$11.7B
| $32.5M | 0.06% |
183,844
-25,889
| -12% | -$4.7M |
|
120
Chegg
CHGG
$98.4M
| $32.3M | 0.06% |
837,787
+41,024
| +5% | +$1.55M |
|
|
RP
121
DELISTED
RealPage, Inc.
RP
| $32.2M | 0.06% |
547,824
-15,411
| -3% | -$933K |
|
|
GTLS
122
DELISTED
Chart Industries
GTLS
| $31.9M | 0.06% |
414,892
+124,596
| +43% | +$10.2M |
|
123
CONMED
CNMD
$1.49B
| $31.8M | 0.06% |
371,327
+145,670
| +65% | +$12M |
|
|
IAA
124
DELISTED
IAA, Inc. Common Stock
IAA
| $31.7M | 0.06% |
+817,528
| New | +$31.7M |
|
125
Monolithic Power Systems
MPWR
$66.8B
| $31.5M | 0.06% |
232,154
+11,367
| +5% | +$1.55M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.